2025年上半年,广药白云山旗下核心子公司王老吉大健康公司交出了一份看似回暖的成绩单:主营业务收入64.99亿元,同比增长8.38%;净利润12.95亿元,增幅达15.87%。这一数据结束了2024年营收净利润双降的颓势,也让外界对其重返增长轨道产生期待。然而,若将时间轴拉长至近六年,王老吉的业绩波动更像是一场"过山车"式的震荡,其背后折射出的行业困境与管理阵痛,远比短期数据反弹更值得关注。业绩...
Source Link2025年上半年,广药白云山旗下核心子公司王老吉大健康公司交出了一份看似回暖的成绩单:主营业务收入64.99亿元,同比增长8.38%;净利润12.95亿元,增幅达15.87%。这一数据结束了2024年营收净利润双降的颓势,也让外界对其重返增长轨道产生期待。然而,若将时间轴拉长至近六年,王老吉的业绩波动更像是一场"过山车"式的震荡,其背后折射出的行业困境与管理阵痛,远比短期数据反弹更值得关注。业绩...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.